This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AUGX Augmedix (AUGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Augmedix Stock (NASDAQ:AUGX) 30 days 90 days 365 days Advanced Chart Get Augmedix alerts:Sign Up Key Stats Today's Range$2.35▼$2.3550-Day Range$2.29▼$2.3552-Week Range$0.73▼$6.25VolumeN/AAverage Volume635,746 shsMarket Capitalization$115.07 millionP/E RatioN/ADividend YieldN/APrice Target$2.35Consensus RatingHold Company OverviewAugmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.Read More… Receive AUGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter. Email Address AUGX Stock News HeadlinesCommure Completes Merger with AugmedixOctober 2, 2024 | globenewswire.com7 AI Penny Stocks to Watch in OctoberSeptember 27, 2024 | 247wallst.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 17, 2025 | Investors Alley (Ad)STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGXSeptember 6, 2024 | prnewswire.comAUGX Sep 2024 2.500 putAugust 18, 2024 | ca.finance.yahoo.comAUGX Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comAUGX Sep 2024 7.500 callAugust 17, 2024 | ca.finance.yahoo.comAUGX Stock Earnings: Augmedix Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | investorplace.comSee More Headlines AUGX Stock Analysis - Frequently Asked Questions When did Augmedix IPO? Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street served as the underwriters for the IPO. What other stocks do shareholders of Augmedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Augmedix investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Today6/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:AUGX CIK1769804 Webwww.augmedix.com Phone888-669-4885FaxN/AEmployees1,430Year FoundedN/APrice Target and Rating Average Stock Price Target$2.35 High Stock Price Target$2.35 Low Stock Price Target$2.35 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.17 million Net Margins-46.23% Pretax Margin-46.10% Return on Equity-182.36% Return on Assets-43.21% Debt Debt-to-Equity Ratio1.48 Current Ratio1.66 Quick Ratio1.66 Sales & Book Value Annual Sales$51.58 million Price / Sales2.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book4.20Miscellaneous Outstanding Shares48,968,000Free Float43,596,000Market Cap$115.07 million OptionableOptionable Beta-0.22 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:AUGX) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Augmedix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Augmedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.